About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Alberto Sánchez-Fueyo, MD PhD, is Professor of Hepatology, Academic Head of the Institute of Liver Studies at King’s College London, and Honorary Transplant Hepatology Consultant at King’s College Hospital.
His research has focused on understanding the mechanisms of immunological tolerance in transplantation and developing novel immunomodulatory therapies, for which he has received funding from MRC, NIHR, NIH and EU, among others. Additional research interests include the generation of genetically engineered regulatory T cells for immunotherapeutic purposes, which is now being pursued in collaboration with Quell Therapeutics, a King’s spin-off biotech which he contributed to found in 2019.
Abstract: Organ transplantation offers enormous opportunities to manipulate the immune system for therapeutic purposes that have not been sufficiently studied. Dr. Sánchez Fueyo's seminar will address the use of cell therapies to modulate alloimmune responses in organ transplantation and describe the results of recent clinical trials in the context of liver transplantation.
Host: Dr. Oriol Bestard, head of Department of Nephrology and head of group Nephrology and kidney transplantation (VHIR). Transplant Center Seminar supported by eCORE AVANT.
Register here to attend by Zoom: https://gencat.zoom.us/j/98060137010